✦ LIBER ✦

90 Safety and Efficacy of Laquinimod in Inducing Clinical and Biochemical Improvement in Active Crohn's Disease: Results of an Exploratory Trial

✍ Scribed by D'Haens, Geert R.; Colombel, Jean-Frederic; Sandborn, William; Rutgeerts, Paul J.; Feagan, Brian G.

Book ID: 122112610
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 278 KB
Volume: 144
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(13)60070-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P379 Safety and efficacy of laquinimod i

P379 Safety and efficacy of laquinimod in inducing clinical and biochemical improvement in active Crohn's disease: Results of an exploratory trial

✍ D'Haens, G.; Colombel, J.-F.; Sandborn, W.; Rutgeerts, P.; Feagan, B. 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 53 KB

Clinical trial: the safety and short-ter

Clinical trial: the safety and short-term efficacy of recombinant cholera toxin B subunit in the treatment of active Crohn’s disease

✍ P. STÅL; R. BEFRITS; A. RÖNNBLOM; Å. DANIELSSON; O. SUHR; D. STÅHLBERG; A. BRINK 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB

Adalimumab Induces and Maintains Clinica

Adalimumab Induces and Maintains Clinical Response and Remission in Patients With Active Crohn’s Disease: Results of the CHARM Trial

✍ J. Colombel; W.J. Sandborn; P. Rutgeerts; R. Enns; S.B. Hanauer; P. Remo; S. Sch 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Clinical and immunological effects of or

Clinical and immunological effects of ornidazole in active Crohn's disease: An 8 - week open label trial

📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 152 KB

P136 - Efficacy and safety of adalimumab

P136 - Efficacy and safety of adalimumab in children with active Crohn's disease: a prospective, open-label, single-centre trial

✍ F. Civitelli; F. Viola; S. Oliva; F. Nuti; E. Romeo; G. Di Nardo; V. Pannone; O. 📂 Article 📅 2009 🏛 Oxford University Press 🌐 English ⚖ 43 KB

Efficacy and safety of certolizumab pego

Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey

✍ Alain M. Schoepfer; Stephan R. Vavricka; Janek Binek; Christian Felley; Martin G 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB

Background: Switzerland was the first country to approve certolizumab pegol (Cimzia, CZP) for the treatment of patients with moderate to severe Crohn's disease (CD) in September 2007. This phase IV study aimed to evaluate the efficacy and safety of CZP in a Swiss multicenter cohort of practice-based